Stem Cell Research Clears Regulatory, Legal Hurdles
Professor Hank Greely is quoted in the Daily Journal on an FDA approved clinical trial for medical treatment using embryonic stem cells. Mandy Jackson filed this story:
Therapies using controversial embryonic stem cells that made paralyzed rats walk in lab tests are one step closer to helping human patients. The developments could spur movement in the marketplace as well.
The U.S. Food and Drug Administration recently approved Menlo Park-based Geron Corp.'s clinical trial of treatments derived from human embryonic stem cells, making it the first study of its kind with human subjects and a test case on many levels. Researchers, regulators, stem cell activists and lawyers all will be assessing the study's results.
"No matter how much you study it in animals, you don't know how it's going to work in humans until you test it," said Hank Greely, professor at Stanford Law School and director of the university's Center for Law and the Biosciences.
Lawsuits filed to prevent California's funding of embryonic stem cell research concluded two and a half years after voters passed Proposition 71, Greely said. None of the claims were successful.